Endocrine Treatment in Breast Cancer

Prognostic value of intrinsic subtypes in HR+/HER2- breast cancer after CDK4/6 inhibitorsПодробнее

The OPTIMA Clinical Trial - Elissa SimmsПодробнее

Not All Women Who Are Clinically High-Risk Benefit from Extended Endocrine TherapyПодробнее

Help Increase Patient Adherence to Extended Endocrine Therapy RecommendationsПодробнее

The Only Guideline Recognized Test to Predict Extended Endocrine Therapy BenefitПодробнее

SABCS 2024 Highlights: PATINA in HR+/HER2+ breast cancerПодробнее

Why Not Extend Endocrine Therapy for All Patients Who Are Tolerating?Подробнее

EUROPA: radiotherapy versus endocrine therapy in low-risk early breast cancerПодробнее

Are You Making Optimal Extended Endocrine Decisions with Your Patients?Подробнее

Which women with HR+, early-stage breast cancer benefit from extended endocrine therapy?Подробнее

Current and future HER2+, HR- metastatic breast cancer treatment approachesПодробнее

Improving Outcomes with First-Line Endocrine-Based Therapy for Patients with HR-Positive, HER2-Ne...Подробнее

How can patients improve their quality of life while receiving endocrine therapy for breast cancer?Подробнее

Oncology Today with Dr Neil Love: Overcoming Endocrine Resistance in ER-Positive Metastatic Breas...Подробнее

Poster Pearl: Treating ER+/HER2- mBC with Elacestrant and Endocrine TherapyПодробнее

Optimizing Therapy for Patients with Hormone Receptor-Positive Metastatic Breast Cancer Harboring...Подробнее

Potential Role of PROTAC ER Degraders in Therapy for HR-Positive Metastatic Breast Cancer (Lecture)Подробнее

First-Line Endocrine-Based Therapy for Patients with HR+, HER2-Negative Metastatic Breast CancerПодробнее

Improving Outcomes with First-Line Endocrine-Based Therapy for Patients with HR-Positive, HER2-Ne...Подробнее

INAVO120 - FDA Approval of Inavolisib in Endocrine-Resistant, PIK3CA-mut, HR+ Advanced Breast CancerПодробнее